<DOC>
	<DOCNO>NCT01054079</DOCNO>
	<brief_summary>This phase II trial study well cinacalcet hydrochloride work treat men recurrent prostate cancer . Cinacalcet hydrochloride may effective lower prostate-specific antigen ( PSA ) level patient recurrent prostate cancer respond previous treatment</brief_summary>
	<brief_title>Cinacalcet Hydrochloride Treating Men With Recurrent Prostate Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To test hypothesis once-daily treatment 30 mg cinacalcet hydrochloride ( Sensipar ) reduce rate rise serum prostate-specific antigen ( PSA ) compare pre-treatment PSA value subject biochemically recurrent prostate cancer fail definitive local therapy . OUTLINE : Patients receive cinacalcet hydrochloride orally ( PO ) daily ( QD ) 20 week absence disease progression unacceptable toxicity . After completion study treatment , patient follow 4 week .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>Patients must histologically cytologically confirm adenocarcinoma prostate For patient recurrent disease follow surgery first line therapy ( `` surgical failure '' ) PSA requirement 0.2 ng/ml For patient recurrent disease follow radiation first line therapy , eligibility follow `` Phoenix criterion '' , , rise 2 ng/mL PSA nadir Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 Granulocytes &gt; = 1000/uL Serum creatinine = &lt; 2.0 mg/dl Total serum calcium &gt; 9.0 &lt; 10.5 mg/dl Total bilirubin = &lt; 2.0 mg/dl Platelet count &gt; =100,000/uL Hemoglobin ( Hgb ) &gt; = 9 g/dL Total testosterone &gt; = 50 ng/dL Ability understand willingness sign write informed consent document ( either directly via legally authorize representative ) Serious medical illness would limit survival less 3 month Active , uncontrolled bacterial , viral fungal infection Hemorrhagic disorder Any radiographic evidence metastatic disease include positive bone scan compute tomography ( CT ) abdomen/pelvis History hypocalcemia seizure disorder Patients know hypersensitivity component cinacalcet ( cinacalcet hydrochloride )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>